Effectiveness of A Levonorgestrel-Releasing Intrauterine System Versus Hysteroscopic Treatment for Abnormal Uterine Bleeding in Women with Cesarean Scar Defects: A Systematic Review and Meta-Analysis.

Abstract

<b>Background/Objectives</b>: To assess the effectiveness of the levonorgestrel-releasing intrauterine device (LNG-IUD) compared to hysteroscopic resection for managing women with symptomatic cesarean scar defects (CSDs). <b>Methods</b>: This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive search of four electronic databases was conducted to identify studies comparing LNG-IUD with hysteroscopic management for symptomatic CSDs. Studies reporting outcomes of bleeding and spotting days and effectiveness rates were included. Quality assessment was performed using the ROBINS-I and RoB-2 tools. <b>Results</b>: Three studies involving 344 patients met the inclusion criteria. At 6 months, LNG-IUD use significantly reduced total bleeding days (MD -4.13; 95% CI: -5.17 to -3.09; <i>p</i> < 0.00001) and spotting days (MD 1.90; 95% CI: 0.43 to 3.37; <i>p</i> = 0.01) compared to hysteroscopic treatment. By 12 months, LNG-IUD demonstrated superior effectiveness (OR 3.46; 95% CI: 1.53 to 7.80; <i>p</i> = 0.003), with fewer total bleeding days (MD -5.69; 95% CI: -6.55 to -4.83; <i>p</i> < 0.00001) and spotting days (MD 3.09; 95% CI: 1.49 to 4.69; <i>p</i> = 0.0002). Approximately 50% of LNG-IUD users experienced amenorrhea within 1 year. <b>Conclusions</b>: LNG-IUD offers a minimally invasive and effective alternative to hysteroscopic resection for women with symptomatic CSD and no desire for future pregnancies. Its role should be considered in clinical practice, but further research is needed to validate these findings and define its long-term benefits and limitations.